PRRT2 and neoplasm: We first tested the effects of BMS-754807 in tumor neurospheres derived from mouse DIPG driven by PDGF-B overexpression, p53 loss, and either the wild type H3.3 histone (PHC) or the mutant H3.3-K27M histone (PKC).